Method for treating AIDS and other immune deficiencies and immune disorders

Claim 2

In the method of treatment of mammals having immunodeficiencies associated with the disturbance of the synthesis of interferons and the production of defective intererons, the improvement comprising parenterally administering to the body thereof a therapeutic amount of inteferon clearing agent to clear said defective interferons from said body.

Claim 3

In the method of treatment of mammals having immunodisorders associated with the disturbance of the synthesis of interferons and the production of defective interferons, the improvement comprising parenterally administering to the body thereof a therapeutic amount of interferon clearing agent to clear said defective interferons from said body.

Claim 4

In the method of treatment of mammals having immunodisorders associated with the disturbance of the synthesis of interferons and the production of defective interferons, the improvement comprising parenterally administering to the body thereof a therapeutic amount of interferon clearing agent to clear said defective interferons from said body.

Claim 5

In the method of treatment of humans having a acquired immune deficiency syndrome associated with the disturbance of the synthesis of interferons and the production of defective inteferons, the improvement comprising parenterally administering to the body thereof a therapeutic amount of interferon clearing agent to clear said defective interferons from said body.

Claim 6

In the method of treatment of humans having a acquired immune deficiency syndrome associated with the disturbance of the synthesis of interferons and the production of defective inteferons, the improvement comprising parenterally administering to the body thereof a therapeutic amount of interferon clearing agent to clear said defective interferons from said body.

Claim 7

In the method of treatment of humans having acquired immune deficiency syndrome, the movement comprising parenterally administering to the body thereof a therapeutic amount of RNA nuclease.

Claim 8

In the method of treatment of humans having acquired immune deficiency syndrome, the movement comprising parenterally administering to the body thereof a therapeutic amount of RNA nuclease.

Claim 9

In the method of treatment of humans having acquired immune deficiency syndrome, the improvement comprising parenterally administering to the body thereof a therapeutic amount of antibody to HTLV-III/LAV.

Claim 10

In the method of treatment of humans having acquired immune deficiency syndrome, the improvement comprising parenterally administering to the body thereof a therapeutic amount of antibody to HTLV-III/LAV.

Claim 11

The method of claim 1, wherein said defective inteferons comprise alpha interferon and said alpha interferon is cleared from said body.

Claim 12

The method of claim 6, wherein said interferon clearing agent is an antibody to alpha interferon.

Claim 13

The method of claim 2, wherein said defective inteferons comprise alpha interferon and said alpha interferon is cleared from said body.

Claim 14

The method of claim 8, wherein said interferon clearing agent is an antibody to alpha interferon.

Claim 15

The method of claim 3, wherein said defective interferons comprise alpha interferon and said alpha interferon is cleared from said body.

Claim 16

The method of claim 10, wherein said interferon clearing agent is an antibody to alpha interferon.

Claim 17

The method of claim 1, wherein said defective inteferons comprise pH labile alpha interferon and said pH labile interferon is cleared form said body.

Claim 18

The method of claim 12, wherein said interferon clearing agent is an antibody to pH labile alpha interferon.

Claim 19

The method of claim 2, wherein said defective inferons comprise pH labile alpha interferon and said pH labile inteferon is cleared from said body.

Claim 20

The method of claim 14, wherein said interferon clearing agent is an antibody to pH alpha interferon.

Claim 21

The method of claim 3, wherein said defective interferons comprise pH labile alpha interferon and said pH labile alpha interferon is cleared form said body.

Claim 22

The method of claim 16, wherein said interferon clearing agent is an antibody to pH alpha interferon.

Claim 23

The method of claim 1, further comprising IgG in said body, a clearing agent for said IgG and said IgG is cleared from said body.

Claim 24

The method of claim 2, further comprising IgG in said body, a clearing agent for said IgG and said IgG is cleared from said body.

Claim 25

The method of claim 3, further comprising Igg in said body, a clearing agent for said IgG and said IgG is cleared from said body.

Claim 26

The method of claim 9, further comprising the parenteral administration of gamma interferon.

Claim 27

The method of claim 15, further comprising the parenteral administration of gamma interferon.

Claim 28

The method of claim 9, further comprising the parenteral adminstration of beta interferon.

Claim 29

The method of claim 15, further comprising the parenteral administration of beta interferon.

Claim 30

The method of claim 9, further comprising the parenteral administration of interleukin 2 and gamma interferon.

Claim 31

The method of claim 9, further comprising the parenteral administration of interleukin 2 and gamma inteferon.

Claim 32

In the method of treatment of mammals having immunodisorders associated with the disturbance of the synthesis of interferons and the production of defective interferons, the improvement comprising selectively removing blood from the body thereof, contacting the removed blood with an immunosorbent for said defective interferons, removing said defective interferons on said immunosorbent and returning said blood free of defective interferons to said body.

Claim 33

In the method of treatment of mammals having immunodisorders associated with the disturbance of the synthesis of interferons and the production of defective interferons, the improvement comprising selectively removing blood from the body thereof, contacting the removed blood with an immunosorbent for said defective interferons, removing said defective interferons on said immunosorbent and returning said blood free of defective interferons to said body.

Claim 34

In the method of treatment of humans having acquired immune deficiency syndrome associated with the disturbance of the synthesis of interferons and the production of defective interferons, the improvement comprising selectively removing blood from the body thereof, contacting the removed blood with an immunosorbent for said defective inteferons, removing said defective intererons on said immunosorbent and returning said blood free of defective interferons to said body.

Claim 35

In the method of treatment of humans having acquired immune deficiency syndrome associated with the disturbance of the synthesis of interferons and the production of defective interferons, the improvement comprising selectively removing blood from the body thereof, contacting the removed blood with an immunosorbent for said defective inteferons, removing said defective intererons on said immunosorbent and returning said blood free of defective interferons to said body.

Claim 36

The method of claim 27, wherein said defective interferons comprises alpha interferon and said alpha interferon is cleared from said body.

Claim 37

The method of claim 29, wherein said immunosorbent is an anitbody to alpha inteferon.

Claim 38

The method of claim 27, wherein said defective interferon comprises pH labile alpha interferon and said pH labile alpha interferon is cleared from said body.

Claim 39

The method of claim 31, wherein said immunosorbent is an antibody to pH labile alpha interferon.

Claim 40

The method of claim 27, further comprising IgG in said body, a clearing agent for said IgG and said IgG is cleared from said body.

Claim 41

In a method of treating diseases comprising the step of selectively clearing the blood of a patient from defective interferons using an apparatus having, in continuous fluid communication, an inlet tube, absorbing means for absorbing and thereby removing defective interferons from the whole blood, and an outlet tube, said method comprising: connecting the inlet tube of said apparatus to a blood vessel of a patient and connecting the outlet tube of said apparatus to a vein of the patient; removing blood form the blood vessel of the patient; passing the removed blood through the absorbing means for absorbing defective interferons to thereby remove the amount of interferons in the blood; and returning the blood to the vein of the patient, the improvement comprising: the step of administering normal inteferon to said patient, said step of administering taking place after the blood has been cleared and returned to the patient and is no longer being removed from the patient.

Claim 42

In a method of treating diseases comprising the step of selectively clearing the blood of a patient from defective interferons using an apparatus having, in continuous fluid communication, an inlet tube, absorbing means for absorbing and thereby removing defective interferons from the whole blood, and an outlet tube, said method comprising: connecting the inlet tube of said apparatus to a blood vessel of a patient and connecting the outlet tube of said apparatus to a vein of the patient; removing blood form the blood vessel of the patient; passing the removed blood through the absorbing means for absorbing defective interferons to thereby remove the amount of interferons in the blood; and returning the blood to the vein of the patient, the improvement comprising: the step of administering normal inteferon to said patient, said step of administering taking place after the blood has been cleared and returned to the patient and is no longer being removed from the patient.

Claim 43

In a method of treating diseases comprising the step of selectively clearing the blood of a patient from defective inteferons using an apparatus having, in continuous fluid communication, an inlet tube, absorbing means for absorbing and thereby removing defective interferons from the whole blood, and an outlet tube, said method comprising: connecting the inlet tube of said apparatus to a blood vessel of a patient and connecting the outlet tube of said apparatus to a vein of the patient; removing blood from the blood vessel of the patient; separating the removed blood into blood cells and plasma; passing the plasma through the absorbing means for absorbing interferons to thereby remove interferons within the plasma; combining the plasma having interferons removed with the blood cells previously removed from the blood; and returning the combined blood cells and plasma to the patient; the improvement comprising: the step of administering normal interferon to said patient, said step of administering taking pace after the blood has been cleared and returned to the patient and is no longer being removed from the patient.

Claim 44

In a method of treating diseases comprising the step of selectively clearing the blood of a patient from defective inteferons using an apparatus having, in continuous fluid communication, an inlet tube, absorbing means for absorbing and thereby removing defective interferons from the whole blood, and an outlet tube, said method comprising: connecting the inlet tube of said apparatus to a blood vessel of a patient and connecting the outlet tube of said apparatus to a vein of the patient; removing blood from the blood vessel of the patient; separating the removed blood into blood cells and plasma; passing the plasma through the absorbing means for absorbing interferons to thereby remove interferons within the plasma; combining the plasma having interferons removed with the blood cells previously removed from the blood; and returning the combined blood cells and plasma to the patient; the improvement comprising: the step of administering normal interferon to said patient, said step of administering taking pace after the blood has been cleared and returned to the patient and is no longer being removed from the patient.

Claim 45

The method of claim 1, wherein said interferon clearing agent is an interferon disintegrating enzyme.

Claim 46

The method of claim 2, wherein said interferon clearing agent is an interferon disintegrating enzyme.

Claim 47

The method of claim 3, wherein said interferon clearing agent is an interferon disintegrating enzyme.

Claim 48

The method of claim 28, further comprising adding an immunosorbent to HTLV-III/LAV to said removed blood.

Claim 49

The method of claim 28, further comprising adding an immunosorbent to microorganisms which cause opportunistic infections to said removed blood.

Claim 50

The method of claim 28, further comprising said immunosorbent containing RNA nuclease.

Claim 51

The method of claim 41, further comprising said immunosorbent containing DNA nuclease.

Claim 52

The method of claim 28, wherein said immunosorbent is an immunosorbent to both HTLV-III/LAV virus and microorganisms which cause opportunistic infections.

Claim 53

The method of claim 3, further comprising parenteral administration of antibody to HTLV-III/LAV virus.

Claim 54

The method of claim 3, further comprising parenteral administration of antibodies to microorganisms which cause opportunistic infections.

Claim 55

The method of claim 3, further comprising parenteral administration of antibodies to both HTLV-III/LAV virus and microorganisms which cause opportunistic infections.

Claim 56

The method of claim 4, further comprising the parenteral administration of DNA nuclease.

Claim 57

In the method of treatment of humans having acquired immune deficiency syndrome, the improvement comprising selectively removing blood from the body thereof, contacting the removed blood with an immunosorbent for HTLV-III/LAV, removing said HTLV-II/LAV on said immunosorbent and returning said blood free of HTLV-III/LAV to said body.

Claim 58

In the method of treatment of humans having acquired immune deficiency syndrome, the improvement comprising selectively removing blood from the body thereof, contacting the removed blood with an immunosorbent for HTLV-III/LAV, removing said HTLV-II/LAV on said immunosorbent and returning said blood free of HTLV-III/LAV to said body.

Claim 59

In the method of treatment of humans having been exposed to the HTLv-III/LAv virus, the improvement comprising parenterally administering to the body thereof a therapeutic amount of antibody to HTLV-III/LAV.

Claim 60

In the method of treatment of humans having been exposed to the HTLv-III/LAv virus, the improvement comprising parenterally administering to the body thereof a therapeutic amount of antibody to HTLV-III/LAV.